Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TTC + MEC
- Development stage
- Unknown
- Lead developer
- TTC Oncology
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
TTC + MEC is a tandem high-dose chemotherapy (HDC) regimen used with autologous stem-cell transplantation (auto-SCT) for treating pediatric brain tumors and neuroblastoma. The regimen consists of two sequential conditioning treatments: TTC (Topotecan, Thiotepa, Carboplatin) followed by MEC (Melphalan, Etoposide, Carboplatin). This approach is particularly used for high-risk brain tumors, young children (under 3 years) to avoid or defer radiotherapy, and in some cases of neuroblastoma.
- Other names
- Topotecan-Thiotepa-Carboplatin + Melphalan-Etoposide-Carboplatin
02
Targets
DNATOP1 (DNA Topoisomerase I)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on TTC + MEC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TTC + MEC.